Mizuho analyst Anthony Petrone lowered the firm’s price target on Medtronic to $95 from $100 and keeps a Buy rating on the shares. The analyst updated medtech and diagnostics models ahead of the Q4 earnings season to reflect feedback from last week’s West Coast broker conference and ongoing hospital/physician channel checks. The general tone suggested the elevated respiratory viral volumes did not impact inpatient volumes, although some pockets of weakness did emerge in outpatient elective procedures, the analyst tells investors in a research note.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on MDT: